Get the Stockscreener App
3.34
4.05%
0.13
Perspective Therapeutics Inc stock is traded at $3.34, with a volume of 105.59K.
It is up +4.05% in the last 24 hours and up +12.08% over the past month.
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is based in Richland, Washington.
See More
Previous Close:
$3.21
Open:
$3.25
24h Volume:
105.59K
Relative Volume:
0.06
Market Cap:
$380.13M
Revenue:
$618.00K
Net Income/Loss:
$-111.65M
P/E Ratio:
-2.3926
EPS:
-1.396
Net Cash Flow:
$-107.53M
1W Performance:
+4.37%
1M Performance:
+12.08%
6M Performance:
-40.88%
1Y Performance:
-6.18%
1-Day Range:
$3.2223
$3.37
1-Week Range:
$3.125
$3.56
52-Week Range:
$1.955
$6.16
Perspective Therapeutics Inc Stock (CATX) Company Profile
Name
Perspective Therapeutics Inc
Sector
Industry
Phone
509-375-1202
Address
350 Hills Street, Suite 106, Richland
Compare CATX vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CATX
Perspective Therapeutics Inc
|
3.33 | 397.25M | 618.00K | -111.65M | -107.53M | -1.396 |
ABT
Abbott Laboratories
|
114.68 | 198.01B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.90 | 130.41B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
92.28 | 120.48B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
49.62 | 75.37B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
89.50 | 53.19B | 6.30B | 1.07B | 1.09B | 1.8406 |
Perspective Therapeutics Inc Stock (CATX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Piper Sandler | Overweight |
| Nov-24-25 | Resumed | Truist | Buy |
| Oct-10-25 | Initiated | BTIG Research | Buy |
| Mar-13-25 | Initiated | H.C. Wainwright | Buy |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-25-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-01-24 | Initiated | Wedbush | Outperform |
| Sep-25-24 | Initiated | Truist | Buy |
| Jul-25-24 | Initiated | BofA Securities | Buy |
| May-09-24 | Initiated | Cantor Fitzgerald | Overweight |
View All
Perspective Therapeutics Inc Stock (CATX) Latest News
BMO Capital Markets Upgrades Perspective Therapeutics (NYSEAMERICAN:CATX) to "Strong-Buy" - MarketBeat
Perspective (CATX) Range: Posts a 8.41% Gain to $3.48 for the Current Session; Chart View - Vinanet
PERSPECTIVE THERAPEUTICS INC : BMO INITIATES COVERAGE WITH OUTPERFORM RATING; PRICE TARGET $11 - Bitget
Perspective Therapeutics Market Sentiment - Benzinga France
CATX Initiated by BMO Capital -- Rating Set to Outperform - GuruFocus
Perspective Therapeutics Price Target Announced at $11.00/Share by BMO Capital - Moomoo
BMO initiates Perspective Therapeutics stock at Outperform, $11 target By Investing.com - Investing.com India
BMO initiates Perspective Therapeutics stock at Outperform, $11 target - Investing.com
BMO Capital Initiates Perspective Therapeutics at Outperform - marketscreener.com
BMO Capital Initiates Coverage on CATX with Outperform Rating, H - GuruFocus
Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
CATX Q1 2026 Earnings: Loss Beats Estimates by 17.25%, Shares Rise 3.23%Revenue Growth Outlook - Vinanet
CATX Maintained by B of A Securities -- Price Target Lowered to $5.00 - GuruFocus
Bank of America Lowers Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target to $5.00 - MarketBeat
BofA Securities Maintains Perspective Therapeutics(CATX.US) With Hold Rating, Cuts Target Price to $5 - Moomoo
Q3 EPS Forecast for Perspective Therapeutics Lifted by Analyst - MarketBeat
BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 - marketscreener.com
Dimensional Fund Advisors LP Acquires 358,540 Shares of Perspective Therapeutics, Inc. $CATX - MarketBeat
Perspective Therapeutics (CATX) Stock Price, News & Analysis - marketbeat.com
Perspective Therapeutics (CATX): Millennium group reports over 5% beneficial stake - Stock Titan
Analysts Set Expectations for Perspective Therapeutics Q1 Earnings - MarketBeat
RBC Capital Sticks to Their Buy Rating for Perspective Therapeutics (CATX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Atossa Therapeutics (ATOS), Corvus Pharmaceuticals (CRVS) and Perspective Therapeutics (CATX) - The Globe and Mail
Perspective Therapeutics, Inc. (CATX) Latest Stock News & Headlines - Yahoo Finance
Perspective Therapeutics (CATX) Gets a Buy from Oppenheimer - The Globe and Mail
Piper Sandler cuts Perspective Therapeutics price target on timing By Investing.com - Investing.com Australia
Perspective Therapeutics's NET Program Data May Allow Phase 3 Trial Start, Value Inflection, RBC Says - marketscreener.com
Piper Sandler cuts Perspective Therapeutics price target on timing - Investing.com
CATX Maintained by Piper Sandler -- Price Target Lowered to $14. - GuruFocus
Perspective Therapeutics (NYSEAMERICAN:CATX) Price Target Lowered to $14.00 at Piper Sandler - MarketBeat
Perspective Therapeutics Price Target Cut to $14.00/Share From $16.00 by Piper Sandler - Moomoo
Perspective Therapeutics (CATX) Climbs 4.7% to $3.14 as Buyers Defend Key SupportValue ETF - Vinanet
Perspective Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
Perspective Therapeutics Reports Q2 Results and Pipeline Progress - TipRanks
Perspective Therapeutics Q2 FY26 net loss widens to $26.8 million - Bitget
Perspective Therapeutics (NYSEAMERICAN:CATX) Announces Quarterly Earnings Results - MarketBeat
Form 8K Perspective Therapeutics Inc For: 10 August By Investing.com - Investing.com Australia
Perspective Therapeutics Q2 EPS beats estimates as sales miss consensus - scanx.trade
Perspective Therapeutics: Q2 Earnings Snapshot - AOL.com
Perspective Therapeutics Reports $26.8 Million Q2 Net Loss - Quiver Quantitative
Perspective Therapeutics (CATX) expands cash to $236.9M while losses widen - Stock Titan
Perspective Therapeutics Q2 net loss widens on higher R&D costs - TradingView
Perspective Therapeutics (NYSE: CATX) grows cash to $237M while advancing Phase 3-ready pipeline - Stock Titan
Perspective Therapeutics Advances VMT-α-NET Toward Phase 3 as Pipeline and Manufacturing Expansion Progresses - Quiver Quantitative
Perspective Therapeutics Provides Recent Business Highlights and Reports 2Q 2026 Results - The Manila Times
Perspective Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MSN Money - MSN
Perspective Therapeutics Inc (CATX) Stock News Today - TradingKey
Perspective Therapeutics Inc (CATX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
State Street Corporation (NYSE: CATX) reports 6.05M-share, 5.3% stake in Perspective - Stock Titan
Perspective Therapeutics (CATX) to Announce Earnings on Wednesday - MarketBeat
Perspective Therapeutics Inc Stock (CATX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.59%
0.75%
Cap:
|
Volume (24h):